Technology
Utilizing a strong force of nature
For injection of larger pharmaceutical volumes subcutaneously, a low flow rate is needed in order for the tissue to absorb the volume injected. In order to achieve this, complex and expensive drive mechanisms with batteries and electronics are commonly used in larger volume, on-body injectors.
The Subcuject WBI utilizes forward osmosis technology to generate force. In simplified terms, two chambers of liquid are separated by a semipermeable membrane. Adding salt to one chamber draws in liquid from the other chamber and hydraulic/mechanical pressure for driving the plunger in the primary drug container is generated. Simple and at a low cost.
Osmosis is a basic and strong force of nature.
Pending patents cover core and peripheral functionality.
Low Cost
The Subcuject WBI only has few moving parts, resulting in inherent low cost of goods sold.
The CoGS is in the range of prefilled autoinjectors.
Patient friendly device
The Subcuject WBI:
- Prefilled, preloaded device
- Invisible/automatic needle insertion and retraction
- Thin needles
- Small size and low weight (76 mm long/55 g for 3 ml device)
- Noiseless in operation
- No patient assembly or setting of the device
- settings or patient assembly of part
- Single use disposable
- No electronics or batteries
Pharma company friendly
The Subcuject device:
- Prefilled, preloaded device
- Few moving parts
- Manufacturing price in the range of prefilled autoinjectors
- Drug shelf life not compromised – at cold storage
- Glass cartridge and standard rubbers as primary packaging
- Can inject high viscosities (at least 100 cP through a G27 needle)
- Currently designed for 3 ml delivery volume with a 5 ml version soon available – can be designed for higher volumes
- No patient assembly or setting of the device i.e. low risk of incorrect use
- As environmentally acceptable for single use as a prefilled autoinjector
Development
The Subcuject WBI is ready for drug specific development programs
The current device is a 3 ml version
Next version of 5 ml is in advanced development
Can be designed for larger volumes
Collaboration with Phillips-Medisize
Subcuject has a close collaboration with Phillips-Medisize on development, manufacturing and commercialization of the Subcuject WBI
News and Media
- Article: OnDrugDelivery, September 2018: Wearable injectors: the perception of inherent expense and complexity
- Article: OnDrugDelivery, May 2019: A patient centric and pharma company centric prefilled wearable bolus injector
- Article: PharmaTech, June 2019: Putting Drug Delivery into patient’s hands: https://www.pharmtech.com/view/putting-drug-delivery-patients-hands
- Article: OnDrugDelivery, September 2019: Development of an osmotic Larger volume wearable bolus injector
- Article: OnDrugDelivery, May 2020: Application of CFD in the development of a wearable bolus injector
- Article: OnDrugDelivery, September 2020: Stability of a wearable injector powered by osmosis
- Press release: February 4, 2021: Phillips-Medisize and Subcuject Announce Collaboration on a Wearable Osmotic Bolus Injector https://www.phillipsmedisize.com/news/phillips-medisize-and-subcuject-announce-collaboration-on-a-wearable-osmotic-bolus-injector/
About
Why
The Subcuject WBI enables gentle injection of larger and more viscous doses compared to auto autoinjectors – at low cost
Biological drugs take up a high number of pharma development pipeline programs. The advantage of biological drugs is the specific targeting. Biologics are being developed for a large number of illnesses.
Biologics have to be injected, and in order to reduce the inconvenience, many drugs are being developed for subcutaneous delivery (as opposed to intravenous administration).
Furthermore, a large number of biologics are being developed for less frequent injection (e.g. weekly or monthly), resulting in larger and more viscous drugs needing to be administered. In order to avoid patients having go to hospitals for injections, it is also of benefit to the patients and to the total cost of health care if injections can be done at home.
The Subcuject WBI is a low cost device that allows for self-administration of larger doses in an easy-to-use and gentle way. The device is a prefilled, small, ready-to-use and noiseless device that is affixed to the skin, activated by a single button press and discarded after use. Needle insertion and retraction is invisible to the patient.
History
Subcuject was founded in 2017 to develop the Subcuject WBI.
The company is privately held and is funded by the Danish venture funds VF Venture and Capnova as well as management and the Board of Directors.
Management
Jesper Roested
20+ years experience in business development, management and venture financing within medtech and life sciences.
...Read More
CEO
20+ years experience in business development, management and venture financing within medtech and life sciences. MSc. In Medical Electronics & Physics.
Previously Partner at VF Venture investing in- and development of medtech companies. CEO of DDD-Diagnostic (nuclear medicine scanners), multiple positions at Novo Nordisk (in drugs and devices) and McKinsey & Co.
Claus Schmidt Møller
B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices.
...Read More
Inventor, Founder and CTO
B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed to major Pharma and drug delivery companies. Mentioned as inventor or co-inventor on 60+ patent families.
Jesper Roested
20+ years experience in business development, management and venture financing within medtech and life sciences. MSc. In Medical Electronics &
...Read More
CEO
20+ years experience in business development, management and venture financing within medtech and life sciences. MSc. In Medical Electronics & Physics.
Previously Partner at VF Venture investing in- and development of medtech companies. CEO of DDD-Diagnostic (nuclear medicine scanners), multiple
Claus Schmidt Møller
B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 &
...Read More
Inventor, Founder and CTO
B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed
Board of Directors
Lars Guldbæk Karlsen
Former pharma executive and PhD in Chemical Engineering.
35 years of pharma management experience from Novo
Read More
Chairman of the Board
Former pharma executive and PhD in Chemical Engineering.
35 years of pharma management experience from Novo Nordisk, hereof 17 years in SVP positions including global responsibility for project portfolio management, business development, device R&D, clinical drug development and quality including 10 years as SVP of Manufacturing Quality.
Nine years as Chairman of the Board at Møller & Devicon A/S (now part of Syntegon Technology), special machine manufacturer to the pharma industry.
Paul Jansen
Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years
...Read More
Member of the board
Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical devices. Extensive experience in the design, development, manufacturing and lifecycle management of medical devices, including Lantus SoloStar. Active member of the International Standards Organisation and currently co-chair of TC84.
Morten Nielsen
Former CEO of Medicom Innovation partner (acquired by Philips Medisize) a leading innovation player within Drug
...Read More
Member of the board
Former CEO of Medicom Innovation partner (acquired by Philips Medisize) a leading innovation player within Drug Delivery device and Connected Health solutions. Previously also leading positions in i.a. PA Consulting Group (Management and Technology Consulting), DGM (notified body) and S&W Medico Teknik. More than 25 years of leadership and operational experience – predominantly within MedTech.
Charlotte Piester
Former international positions in Coloplast and Ambu, experience as CEO and founder from several smaller companies
...Read More
Member of the Board
Former international positions in Coloplast and Ambu, experience as CEO and founder from several smaller companies and CEO for an international oncological knowledge center. Driving growth of companies through consultant company, M&A processes and board member experience. Combined business and clinical background, M&A, Business development and MBA. Author of “MedTech Marketing” for MedTech success.
Lars Stigel
CEO of Capnova, a Danish pre-seed and seed investor. PhD. Since 1998 Lars has been involved
...Read More
Member of the Board
CEO of Capnova, a Danish pre-seed and seed investor. PhD. Since 1998 Lars has been involved in starting and investing in around 140 new companies of which 50 are spin out’s from university and hospital research. Before 1998 he among other positions was in charge of the profiling of university research towards the industry and managed a governmental cross institutional environmental research program.
Claus Demant
E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy
...Read More
Co-founder and Member of the Board
E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy and business development.
International experience from IT, Electronics and MedTech industry. Regional Leadership positions in Creative Labs and SVP position in Daymen Acquisition S.A
Lars Guldbæk Karlsen
Former pharma executive and PhD in Chemical Engineering.
35 years of pharma management experience from Novo Nordisk, hereof 17 years
Read More
Chairman of the Board
Former pharma executive and PhD in Chemical Engineering.
35 years of pharma management experience from Novo Nordisk, hereof 17 years in SVP positions including global responsibility for project portfolio management, business development, device R&D, clinical drug development and quality including 10 years as SVP of Manufacturing Quality.
Nine years as Chairman of the Board at Møller & Devicon A/S (now part of Syntegon Technology), special machine manufacturer to the pharma industry.
Paul Jansen
Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical
...Read More
Member of the board
Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical devices. Extensive experience in the design, development, manufacturing and lifecycle management of medical devices, including Lantus SoloStar. Active member of the International Standards Organisation and currently co-chair of TC84.
Morten Nielsen
Former CEO of Medicom Innovation partner (acquired by Philips Medisize) a leading innovation player within Drug Delivery device and Connected
...Read More
Member of the board
Former CEO of Medicom Innovation partner (acquired by Philips Medisize) a leading innovation player within Drug Delivery device and Connected Health solutions. Previously also leading positions in i.a. PA Consulting Group (Management and Technology Consulting), DGM (notified body) and S&W Medico Teknik. More than 25 years of leadership and operational experience – predominantly within MedTech.
Charlotte Piester
Former international positions in Coloplast and Ambu, experience as CEO and founder from several smaller companies and CEO for an
...Read More
Member of the Board
Former international positions in Coloplast and Ambu, experience as CEO and founder from several smaller companies and CEO for an international oncological knowledge center. Driving growth of companies through consultant company, M&A processes and board member experience. Combined business and clinical background, M&A, Business development and MBA. Author of “MedTech Marketing” for MedTech success.
Lars Stigel
CEO of Capnova, a Danish pre-seed and seed investor. PhD. Since 1998 Lars has been involved in starting and investing
...Read More
Member of the Board
CEO of Capnova, a Danish pre-seed and seed investor. PhD. Since 1998 Lars has been involved in starting and investing in around 140 new companies of which 50 are spin out’s from university and hospital research. Before 1998 he among other positions was in charge of the profiling of university research towards the industry and managed a governmental cross institutional environmental research program.
Claus Demant
E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy and business development.
International
Read More
Co-founder and Member of the Board
E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy and business development.
International experience from IT, Electronics and MedTech industry. Regional Leadership positions in Creative Labs and SVP position in Daymen Acquisition S.A
Contact
The Subcuject WBI is designed for drug/device combinations products, requiring combined development for the specific drug.
Please contact us for discussing your needs.
Jesper Roested
CEO
Phone: +45 2122 7772
jr@subcuject.com
Subcuject ApS
Nordre Strandvej 119, F1
DK-3150 Hellebaek
Denmark
